Ipamorelin Prescribed

Show your work

Ipamorelin references — every claim on this site traces here.

Peer-reviewed studies, reviews, and the human trial, with DOIs and PubMed links.

Back to the researchWhat people report

How to read this list

Every bracketed number on this site — [1], [2], and so on — points to an entry below. The list spans the founding 1998 selectivity paper, the human pharmacokinetic study, the failed Phase 2 trial, the preclinical bone and body-composition work, and the 2024-2026 studies and reviews that make up the recent-research frontier this digest leads with. A few entries are class-level or scaffold studies where ipamorelin was not the tested molecule; those are noted in the text where they are cited so no finding is misattributed.

  1. Raun K, Hansen BS, Johansen NL, Thogersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. ↗
  2. Gobburu JV, Agerso H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412-1416. ↗
  3. Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014;29(12):1527-1534. (NCT00672074) ↗
  4. Johansen PB, Nowak J, Skjaerbaek C, Flyvbjerg A, Andreassen TT, Wilken M, Orskov H. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res. 1999;9(2):106-113. ↗
  5. Lu Z, Ngan MP, Liu JYH, Yang L, Tu L, Chan SW, Giuliano C, Lovati E, Pietra C, Rudd JA. The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism. Physiol Behav. 2024;284:114644. ↗
  6. Stokes AH, Falls JG, Yoon L, Cariello N, Faiola B, Colton HM, Jordan HL, Berridge BR. Integrated approach to early detection of cardiovascular toxicity induced by a ghrelin receptor agonist. Int J Toxicol. 2015;34(2):151-161. ↗
  7. Mosa A, et al. Unacylated ghrelin protects against age-related loss of muscle mass and contractile dysfunction in skeletal muscle. Aging Cell. 2024;23(9):e14323. ↗
  8. Worm DJ, et al. A stable meta-carborane enables the generation of boron-rich peptide agonists targeting the ghrelin receptor. J Pept Sci. 2018;24:e3119. ↗
  9. Fowkes MM, et al. Peptidomimetic growth hormone secretagogue derivatives for positron emission tomography imaging of the ghrelin receptor. Eur J Med Chem. 2018;157:1500-1511. ↗
  10. Krug O, et al. Analysis of new growth promoting black market products. Growth Horm IGF Res. 2018;41:1-6. ↗
  11. Gajda PM, et al. Glycine-modified growth hormone secretagogues identified in seized doping material. Drug Test Anal. 2019;11:350-354. ↗
  12. Coutinho LFD, et al. A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review. J Sports Med Phys Fitness. 2026. ↗
  13. Gouda M, et al. The influence of ghrelin agonist ipamorelin acetate on the hypothalamic-pituitary-testicular axis in a cichlid fish, Oreochromis mossambicus. Anim Reprod Sci. 2024. ↗
  14. Rahman OF, et al. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. J Am Acad Orthop Surg Glob Res Rev. 2026. ↗
  15. Mavrych V, et al. Therapeutic peptides in gerontology: mechanisms and applications for healthy aging. Front Aging. 2026. ↗
  16. Lall S, Tung LY, Ohlsson C, Jansson JO, Dickson SL. Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues. Biochem Biophys Res Commun. 2001;280(1):132-138. ↗
  17. Lawrence CB, Snape AC, Baudoin FM, Luckman SM. Acute central ghrelin and GH secretagogues induce feeding and activate brain appetite centers. Endocrinology. 2002;143(1):155-162. ↗
  18. Adeghate E, Ponery AS. Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats. Neuro Endocrinol Lett. 2004;25(6):403-406. ↗